Total Payments
$187,984
2024 Payments
$11,470
Companies
28
Transactions
507
Medicare Patients
17,236
Medicare Billing
$13.0M
Payment Breakdown by Category
Other$119,681 (63.7%)
Consulting$42,369 (22.5%)
Food & Beverage$15,656 (8.3%)
Travel$10,057 (5.4%)
Education$220.71 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $110,205 | 31 | 58.6% |
| Consulting Fee | $42,369 | 20 | 22.5% |
| Food and Beverage | $15,656 | 390 | 8.3% |
| Travel and Lodging | $10,057 | 51 | 5.4% |
| Compensation for serving as faculty or as a speaker for a medical education program | $6,975 | 8 | 3.7% |
| Honoraria | $2,390 | 2 | 1.3% |
| Education | $220.71 | 4 | 0.1% |
| Entertainment | $110.77 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $57,340 | 96 | $0 (2019) |
| ABBVIE INC. | $36,122 | 110 | $0 (2024) |
| EyePoint Pharmaceuticals US, Inc. | $23,931 | 24 | $0 (2023) |
| Genentech USA, Inc. | $21,429 | 64 | $0 (2024) |
| Bausch & Lomb Americas Inc. | $19,732 | 27 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $18,298 | 39 | $0 (2024) |
| Alimera Sciences, Inc. | $4,361 | 22 | $0 (2024) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $1,655 | 8 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $1,423 | 16 | $0 (2021) |
| Apellis Pharmaceuticals, Inc. | $591.85 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $11,470 | 60 | Bausch & Lomb Americas Inc. ($6,176) |
| 2023 | $27,949 | 63 | Genentech USA, Inc. ($19,658) |
| 2022 | $18,085 | 56 | EyePoint Pharmaceuticals US, Inc. ($8,637) |
| 2021 | $8,210 | 37 | EyePoint Pharmaceuticals US, Inc. ($3,472) |
| 2020 | $15,245 | 19 | Mallinckrodt Hospital Products Inc. ($15,168) |
| 2019 | $42,963 | 73 | Mallinckrodt Enterprises LLC ($27,750) |
| 2018 | $46,068 | 121 | Mallinckrodt LLC ($22,332) |
| 2017 | $17,995 | 78 | AbbVie, Inc. ($10,077) |
All Payment Transactions
507 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $23.11 | General |
| Category: Ophthalmology | ||||||
| 11/22/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $38.03 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/18/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $28.32 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/15/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $38.42 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/14/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $23.37 | General |
| Category: Ophthalmology | ||||||
| 11/13/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $644.41 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 11/06/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $33.48 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/05/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $22.97 | General |
| Category: EYE CARE | ||||||
| 10/31/2024 | Sandoz Inc. | Cimerli (Biological) | Food and Beverage | In-kind items and services | $26.15 | General |
| Category: Ophthalmology | ||||||
| 10/23/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $92.91 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 10/22/2024 | Genentech USA, Inc. | Susvimo (Drug), Vabysmo | Consulting Fee | Cash or cash equivalent | $705.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/21/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $29.69 | General |
| Category: Ophthalmology | ||||||
| 10/19/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Ophthalmology | ||||||
| 10/19/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $77.04 | General |
| Category: Ophthalmology | ||||||
| 10/19/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $41.47 | General |
| Category: IMMUNOLOGY | ||||||
| 10/11/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $28.54 | General |
| Category: EYE CARE | ||||||
| 10/08/2024 | Sandoz Inc. | Cimerli (Biological) | Food and Beverage | In-kind items and services | $20.23 | General |
| Category: Ophthalmology | ||||||
| 10/04/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $216.49 | General |
| Category: Ophthalmology | ||||||
| 10/01/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $29.02 | General |
| Category: Immunology and Ophthalmology | ||||||
| 09/12/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $25.74 | General |
| Category: Ophthalmology | ||||||
| 09/12/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $24.23 | General |
| Category: Ophthalmology | ||||||
| 09/10/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $427.36 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 09/09/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $98.11 | General |
| Category: Immunology and Ophthalmology | ||||||
| 08/30/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $35.38 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 08/30/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $1.47 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 26 | 4,350 | 74,847 | $11.9M | $3.5M |
| 2022 | 28 | 4,668 | 25,547 | $11.3M | $3.3M |
| 2021 | 24 | 4,399 | 13,154 | $11.2M | $3.3M |
| 2020 | 18 | 3,819 | 13,115 | $10.2M | $3.1M |
Total Patients
17,236
Total Services
126,663
Medicare Billing
$13.0M
Procedure Codes
98
All Medicare Procedures & Services
98 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 263 | 63,555 | $5.0M | $1.7M | 34.8% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 130 | 989 | $2.2M | $668,288 | 30.4% |
| J3490 | Unclassified drugs | Office | 2023 | 68 | 113 | $681,800 | $211,575 | 31.0% |
| 67028 | Injection of drug into eye | Office | 2023 | 443 | 1,537 | $1.8M | $144,873 | 7.9% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2023 | 37 | 743 | $306,006 | $108,175 | 35.4% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 25 | 840 | $280,006 | $101,103 | 36.1% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 719 | 1,024 | $204,800 | $89,133 | 43.5% |
| 92134 | Imaging of retina | Office | 2023 | 1,081 | 2,836 | $283,486 | $84,622 | 29.9% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 16 | 265 | $132,500 | $48,763 | 36.8% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 448 | 658 | $131,600 | $44,715 | 34.0% |
| J3299 | Injection, triamcinolone acetonide (xipere), 1 mg | Office | 2023 | 20 | 976 | $99,820 | $32,801 | 32.9% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 29 | 30 | $171,000 | $27,217 | 15.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 333 | 456 | $50,160 | $26,681 | 53.2% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 196 | 196 | $53,900 | $20,449 | 37.9% |
| 67036 | Removal of eye fluid (vitreous) between lens and retina | Facility | 2023 | 23 | 26 | $104,000 | $18,495 | 17.8% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 138 | 156 | $44,460 | $15,741 | 35.4% |
| 67041 | Removal of membrane of retina | Facility | 2023 | 15 | 15 | $82,500 | $13,569 | 16.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 69 | 101 | $24,240 | $12,884 | 53.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 124 | 153 | $26,010 | $12,852 | 49.4% |
| 67108 | Repair of detached retina with drainage and removal of eye fluid between lens and retina | Facility | 2023 | 11 | 14 | $84,000 | $11,916 | 14.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 50 | 50 | $17,500 | $8,183 | 46.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 60 | 60 | $16,800 | $7,106 | 42.3% |
| 67228 | Destruction of leaking blood vessels of retina using laser | Facility | 2023 | 15 | 16 | $48,000 | $4,626 | 9.6% |
| 92083 | Exam of visual field with extended testing | Office | 2023 | 12 | 13 | $1,950 | $596.31 | 30.6% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 12 | 12 | $3,660 | $463.36 | 12.7% |
About Dr. Robert Wang, M.D
Dr. Robert Wang, M.D is a Ophthalmology healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1568447175.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Wang, M.D has received a total of $187,984 in payments from pharmaceutical and medical device companies, with $11,470 received in 2024. These payments were reported across 507 transactions from 28 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($110,205).
As a Medicare-enrolled provider, Wang has provided services to 17,236 Medicare beneficiaries, totaling 126,663 services with total Medicare billing of $13.0M. Data is available for 4 years (2020–2023), covering 98 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Dallas, TX
- Active Since 12/07/2005
- Last Updated 02/06/2013
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1568447175
Products in Payments
- ACTHAR (Biological) $75,639
- Humira (Biological) $35,616
- YUTIQ (Drug) $24,947
- XIPERE (Drug) $21,232
- Vabysmo (Drug) $13,698
- Susvimo (Drug) $2,217
- ILUVIEN (Drug) $1,663
- BEOVU (Drug) $1,209
- Lucentis (Biological) $867.51
- OZURDEX (Drug) $552.52
- Syfovre (Drug) $493.35
- Cimerli (Biological) $475.10
- DEXYCU (Drug) $353.55
- PURIFIED CORTROPHIN GEL (Drug) $347.30
- Izervay (Drug) $312.19
- VABYSMO (Drug) $216.86
- EYLEA (Biological) $209.45
- EYLEA HD (Biological) $152.92
- ForeseeHome (Device) $141.46
- Iluvien (Drug) $137.22
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Dallas
Dr. Oluwatosin Smith, M.d, M.D
Ophthalmology — Payments: $1.5M
Ophthalmology $1.5M
Davinder Grover, M.d, Mph, M.D, MPH
Ophthalmology — Payments: $1.0M
Ophthalmology $1.0M
Dr. Ashkan Abbey, M.d, M.D
Ophthalmology — Payments: $624,167
Ophthalmology $624,167
Dr. Karl Csaky, Md, MD
Ophthalmology — Payments: $583,703
Ophthalmology $583,703
Jeffrey Whitman, M.d, M.D
Ophthalmology — Payments: $272,915
Ophthalmology $272,915
Arvind Neelakantan, Md, MD
Ophthalmology — Payments: $112,729
Ophthalmology $112,729